TrialBritish journal of cancer2018

Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial.

Anne Katrin Berger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.